BETA1 AND BETA2 ADRENOCEPTOR SIGNALING IN CARDIAC MYOCYTE

心肌细胞中的 Beta1 和 Beta2 肾上腺素信号传导

基本信息

项目摘要

3 Adrenoceptors (pARs) signaling is finely regulated to control cardiovascular function in response to sympathetic nervous system input (norepinephrine) and to adrenaline (epinephrine) from the adrenal gland. In animal hearts, two highly homologous pARs (P1AR and P2AR) are stimulated by catecholamines to enhance contractility and heart rate. Chronic stimulation of cardiac (3ARs by elevated circulating catecholamines as well as decreased cardiac (31AR density is clinically associated with heart failure. The primary functions attributed to GPCRs are ligand binding and G-protein coupling. However, the specific and diversified functional properties of GPCRs in vivo involve kinetic receptor conformational changes for binding different partners in signaling complexes, and the localization of receptor signaling complexes in cell type- specific manner. We hypothesize that norepinephrine and epinephrine can activate distinct signaling pathways for both (31AR and (32AR in cardiac myocyte. We have chosen the neonatal cardiac myocyte isolated from the PAR gene deficiency mice as a model system to study the functional roles of ligand- receptor interactions in differentiated cells. The goals of this proposal are (1) to characterize (31 AR and |32AR subtype-specific signaling by different agonists in neonatal myocytes, (2) define the cellular and biochemical properties of (31 AR and P2AR under norepinephrine and epinephrine stimulation in cardiac myocytes, (3) to characterize the subcellular distribution of (31ARand (32AR, and other signaling molecules under norepinephrine and epinephrine stimulation in cardiac myocyte, (4) to identify receptor interaction domains and their targeted proteins, and to characterize the receptor signaling complex formation and stability upon agonist stimulation. A better understanding of agonist-induced PAR conformationchange for the organization of signaling complexes may facilitate new drug designs and suggest new clinical applications in treating various cardiovascular diseases.
3肾上腺素受体(PARs)信号被精细调节以控制心血管功能 交感神经系统的输入(去甲肾上腺素)和肾上腺的肾上腺素(肾上腺素)。 在动物心脏中,儿茶酚胺刺激两个高度同源的Pars(P1AR和P2AR)以 增强收缩能力和心率。慢性心脏刺激(3ARs),通过升高循环 儿茶酚胺和心脏(31AR密度降低)在临床上与心力衰竭有关。这个 GPCRs的主要功能是配体结合和G蛋白偶联。然而,具体的和 GPCRs在体内的多种功能特性涉及结合受体的动态构象变化 信号复合体中的不同伙伴,以及受体信号复合体在细胞类型中的定位- 具体的方式。我们假设去甲肾上腺素和肾上腺素可以激活不同的信号。 (31AR和(32AR)在心肌细胞中的作用途径。我们选择了新生心肌细胞 从PAR基因缺陷小鼠分离作为模型系统,研究配体-2的功能作用 分化细胞中的受体相互作用。本提案的目标是(1)描述(31 AR和 新生儿心肌细胞中不同激动剂的32AR亚型特异性信号转导,(2)定义细胞和 心脏去甲肾上腺素和肾上腺素刺激下(31AR和P2AR)的生化特性 肌细胞,(3)表征(31AR和(32AR)及其他信号分子的亚细胞分布 在去甲肾上腺素和肾上腺素刺激下的心肌细胞,(4)识别受体相互作用 结构域及其靶蛋白,并表征受体信号复合体的形成和 激动剂刺激下的稳定性。更好地理解激动剂诱导的PAR构象变化 信号复合体的组织可以促进新药设计和建议新的临床 在治疗各种心血管疾病中的应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YANG K XIANG其他文献

YANG K XIANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YANG K XIANG', 18)}}的其他基金

Phosphodiesterases govern nuclear cAMP signaling for gene expression
磷酸二酯酶控制基因表达的核 cAMP 信号传导
  • 批准号:
    10717183
  • 财政年份:
    2023
  • 资助金额:
    $ 29.25万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10369578
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
Desensitization of beta1 adrenergic receptor-nitric oxide signaling in cardiac diseases
心脏病中β1肾上腺素受体-一氧化氮信号的脱敏
  • 批准号:
    10367949
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
Desensitization of beta1 adrenergic receptor-nitric oxide signaling in cardiac diseases
心脏病中β1肾上腺素受体-一氧化氮信号的脱敏
  • 批准号:
    10618826
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10513328
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
Molecular Regulation of cardiac adrenergic signaling
心脏肾上腺素信号传导的分子调节
  • 批准号:
    10425249
  • 财政年份:
    2019
  • 资助金额:
    $ 29.25万
  • 项目类别:
Molecular Regulation of cardiac adrenergic signaling
心脏肾上腺素信号传导的分子调节
  • 批准号:
    10155584
  • 财政年份:
    2019
  • 资助金额:
    $ 29.25万
  • 项目类别:
Molecular Regulation of cardiac adrenergic signaling
心脏肾上腺素信号传导的分子调节
  • 批准号:
    9922716
  • 财政年份:
    2019
  • 资助金额:
    $ 29.25万
  • 项目类别:
Novel mechanism on subpopulation-dependent biased GPCR signaling in neurons
神经元亚群依赖性偏向 GPCR 信号传导的新机制
  • 批准号:
    10174956
  • 财政年份:
    2018
  • 资助金额:
    $ 29.25万
  • 项目类别:
Novel mechanism on subpopulation-dependent biased GPCR signaling in neurons
神经元亚群依赖性偏向 GPCR 信号传导的新机制
  • 批准号:
    9929881
  • 财政年份:
    2018
  • 资助金额:
    $ 29.25万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 29.25万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 29.25万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 29.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了